Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study - Wedemeyer, H; Aleman, S; Brunetto, M (J Hepatol, 2023)
et al.